InDex Gets Cash Boost For Phase III Ulcerative Colitis Drug
Swedish Firm's Cobitolimod Could Be A Blockbuster
The Stockholm-based company is in a position to start the Phase III program for its ulcerative colitis candidate after raising over $64m in a rights issue.
You may also be interested in...
Almirall has returned ulcerative colitis therapy Kappaproct to its originator company InDex Pharmaceuticals.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.